| Bioactivity | Antileishmanial agent-19 (Compound F27) is an antileishmanial agent, with a IC50 of 3.39 μM for L. donovani promastigotes. Antileishmanial agent-19 inhibits Leishmania prolyl-tRNA synthetase. Antileishmanial agent-19 inhibits host PI3K/Akt/CREB axis-mediated IL-10 secretion. Antileishmanial agent-19 induces autophagy-mediated apoptosis in L. donovani promastigotes. Antileishmanial agent-19 reduces parasite burden in L.d-infected animals[1]. |
| Name | Antileishmanial agent-19 |
| Formula | C22H18N4O3 |
| Molar Mass | 386.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ansari A, et al. Discovery, SAR and mechanistic studies of quinazolinone-based acetamide derivatives in experimental visceral leishmaniasis. Eur J Med Chem. 2023 Sep 5;257:115524. |
Antileishmanial agent-19
CAS: F: C22H18N4O3 W: 386.40
Antileishmanial agent-19 (Compound F27) is an antileishmanial agent, with a IC50 of 3.39 μM for L. donovani promastigot
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.